NAGE
Niagen Bioscience, Inc.Company Information
- Company Name
- Niagen Bioscience, Inc.
- CIK
- CIK0001386570
- Category
- Large accelerated filer
- Ticker: Exchange
- NAGE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2833
- SIC Description
- Medicinal Chemicals & Botanical Products
- Ticker
- NAGE
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-14
- Last sale
- 2024-12-13
- Shares purchased (TTM)
- 7,645.16
- Shares sold (TTM)
- 37,161
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 30,124,527
- Shares outstanding
- 79,322,000
- Ownership
- 37.98%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -5.19%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | - | - | - | - | - | - | 8 | - | - | - | 5 | -1 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 67 | 67 | 65 | 64 | 60 | 56 | 45 | 32 | 28 | 28 | 27 | 27 | ||||||
| Accounts Receivable Net Current | 9 | 13 | 10 | 9 | 10 | 7 | 8 | 7 | 8 | 7 | - | - | ||||||
| Inventory Gross | 21 | 24 | 20 | - | - | - | 9 | - | - | - | - | - | ||||||
| Inventory Net | - | 24 | - | 19 | 14 | 11 | 9 | 11 | 12 | 12 | 15 | 13 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | 0 | 0 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 98 | 105 | 97 | 94 | 87 | 76 | 64 | 52 | 49 | 49 | 50 | 47 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | 5 | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 107 | 114 | 106 | 98 | 92 | 81 | 68 | 57 | 54 | 54 | 55 | 53 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 13 | 11 | 13 | 14 | 11 | 9 | 7 | 8 | 8 | 10 | 9 | ||||||
| Accrued Liabilities Current | 4 | 8 | 8 | 9 | 7 | 9 | 8 | 10 | 9 | 10 | 9 | 9 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Compensation Liability Current | 1 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Current | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 15 | 23 | 20 | 23 | 22 | 21 | 18 | 18 | 18 | 19 | 21 | 19 | ||||||
| Contract With Customer Liability Noncurrent | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Compensation Liability Classified Noncurrent | 5 | 5 | 5 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 24 | 32 | 30 | 27 | 27 | 26 | 22 | 22 | 23 | 25 | 27 | 26 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 240 | 240 | 241 | 239 | 237 | 232 | 228 | 223 | 222 | 220 | 219 | 218 | ||||||
| Retained Earnings Accumulated Deficit | -157 | -158 | -165 | -169 | -173 | -177 | -182 | -189 | -191 | -191 | -190 | -191 | ||||||
| Translation Adjustment Functional To Reporting Currency Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 83 | 82 | 77 | 71 | 64 | 55 | 46 | 34 | 31 | 29 | 28 | 27 | ||||||
| Liabilities And Stockholders Equity | 107 | 114 | 106 | 98 | 92 | 81 | 68 | 57 | 54 | 54 | 55 | 53 | ||||||
| Restricted Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Related Party | - | - | - | - | - | - | 0 | -2 | 1 | 3 | 3 | 0 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 79 | 79 | 80 | 80 | 80 | 78 | 77 | 76 | 75 | 75 | 75 | 75 | ||||||
| Shares Outstanding | 79 | 79 | 80 | 80 | 80 | 78 | 77 | 76 | 75 | 75 | 75 | 75 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNiagen Bioscience, Inc. (NAGE) — SEC Financial Statements & Analysis
Niagen Bioscience, Inc. (NAGE) is a medicinal chemicals & botanical products company, incorporated in DE. Niagen Bioscience, Inc. trades on Nasdaq as: NAGE. Niagen Bioscience, Inc. (NAGE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Niagen Bioscience, Inc. carries a market cap of $253.04M, a P/E ratio of 15.82x, a P/B ratio of 3.07x, a P/S ratio of 1.96x, an enterprise value of $186.30M, and an EV/EBITDA multiple of 16.74x. On profitability, it posts a gross margin of 64.24%, an operating margin of 8.21%, a net margin of 12.39%, a Return on Equity (ROE) of 21.80%, a Return on Assets (ROA) of 16.14%, and a Return on Invested Capital (ROIC) of 81.50%. Per share, it reports EPS of $0.20, diluted EPS of $0.19, free cash flow per share of $0.07, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.99% year-over-year, net income growth of -9.80% year-over-year, and EPS growth of -9.89% year-over-year. On the balance sheet, it maintains a current ratio of 6.50x, a quick ratio of 5.00x, working capital of $82.74M, a debt-to-equity ratio of 0.29x, a debt ratio of 0.23, an interest coverage ratio of 6.43x, free cash flow of $5.95M (TTM), and net debt of $-66.74M. Figures sourced from SEC EDGAR.
- Market Cap
- $253.04M
- P/E TTM
- 15.82x
- EPS TTM
- $0.20
- P/B TTM
- 3.07x
- ROE TTM
- 21.80%
- ROA TTM
- 16.14%
- Debt To Equity
- 0.29x
- Free Cash Flow TTM
- $5.95M
- Net Revenue TTM Growth 1Y
- 10.99%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Niagen Bioscience, Inc. in?
Niagen Bioscience, Inc. (NAGE) operates in the Medicinal Chemicals & Botanical Products industry.
What exchange does NAGE trade on?
Niagen Bioscience, Inc. (NAGE) trades on the Nasdaq.
Where is Niagen Bioscience, Inc. incorporated?
Niagen Bioscience, Inc. is incorporated in DE.
When was Niagen Bioscience, Inc. (NAGE)'s most recent SEC filing?
Niagen Bioscience, Inc. (NAGE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is NAGE's market cap?
Niagen Bioscience, Inc. (NAGE) has a market capitalization of $253.04M as of 2026-06-30.
What is NAGE's P/E ratio?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month P/E ratio is 15.82x as of 2026-06-30.
What is NAGE's EPS (earnings per share)?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month EPS is $0.20 as of 2026-06-30.
What is NAGE's ROE (return on equity)?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month Return on Equity (ROE) is 21.80% as of 2026-06-30.
What is NAGE's ROA (return on assets)?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month Return on Assets (ROA) is 16.14% as of 2026-06-30.
What is NAGE's ROIC (return on invested capital)?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month Return on Invested Capital (ROIC) is 81.50% as of 2026-06-30.
What is NAGE's EV/EBITDA?
Niagen Bioscience, Inc. (NAGE)'s trailing twelve month EV/EBITDA is 16.74x as of 2026-06-30.